S Recombinant Monoclonal Antibody

Code CSB-RA33245A1GMY
Size US$210
Order now
Image
  • The Binding Activity of SARS-CoV-2-S Antibody with SARS-CoV-2-S
    Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S (CSB-MP3324GMY) at 2 μg/ml can bind SARS-CoV-2-S Antibody, the EC50 is 42.83 ng/ml.
  • The Binding Activity of SARS-CoV-2-S Antibody with SARS-CoV-2-S1-RBD
    Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) at 2 μg/ml can bind SARS-CoV-2-S Antibody, the EC50 is 29.51 ng/ml.
  • In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33245A1GMY) is clean, the detection limit can be as low as 223.2ng/ml (15.625ng/0.07ml), and the sensitivity is very good.
  • Binding signal of SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) and ACE2 protein-HRP conjugate (CSB-MP866317HU) was inhibited聽by S Antibody (CSB-RA33245A1GMY) with the IC50 is 23.32 nM.
  • Binding signal of SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) and ACE2 protein-HRP conjugate (CSB-MP866317HU) was inhibited by S Antibody (CSB-RA33245A1GMY) with the IC50 is 2.38 μg/ml.
  • ELISA: Immobilize various types of SARS proteins at concentration of 2μg/ml on solid substrate, then react with SARS-CoV-2-S Antibody at concentration of 100μg/ml, 10μg/ml and 1μg/ml. It shows the SARS-CoV-2-S Antibody (CSB-RA33245A1GMY) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with MERS-CoV, SARS-CoV, HCoV-OC43 or HCoV-229E.
  • The Binding Activity of S protein with S Recombinant Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized S at 2 μg/ml can bind S Recombinant Antibody, the EC50 of S Recombinant Antibody.
  • The Binding Activity of S protein with S Recombinant Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized S at 2 μg/ml can bind S Recombinant Antibody, the EC50 of S Recombinant Antibody.
  • The Binding Activity of S protein with S Recombinant Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized S at 2 μg/ml can bind S Recombinant Antibody, the EC50 of S Recombinant Antibody. The Binding Activity of S protein with S Recombinant Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized S at 2 μg/ml can bind S.
  • The Binding Activity of S protein with S Recombinant Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized S at 2 μg/ml can bind S Recombinant Antibody, the EC50 of S Recombinant Antibody.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Alternative Names
S; 2; Spike glycoprotein; S glycoprotein; E2; Peplomer protein)
Species Reactivity
Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV)
Immunogen
Recombinant Human Novel Coronavirus Spike glycoprotein (S) (16-685aa) (CSB-MP3324GMY)
Immunogen Species
Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Mouse scFv fusion with human IgG1 Fc
Clone No.
H6
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, GICA, Neutralising
Recommended Dilution
Application Recommended Dilution
ELISA 1:10000-1:50000
GICA 1:500-1:5000
Neutralising 1:50-1:10000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

CUSABIO induced an immune response by immunizing a mouse with a human SARS-CoV-2 spike glycoprotein (S) (16-685aa). B cells were then isolated from the immunized mouse and fused with myeloma cells, resulting in the formation of hybridoma cells. From the screened hybridoma cells, a single clone that produces the desired human SARS-CoV-2 S-specific antibody was selected. RNA was extracted from the selected hybridoma cells and the variable regions of the human SARS-CoV-2 S antibody were isolated and amplified using reverse transcription PCR. Insert the DNA sequence encoding the mouse single-chain variable fragment (scFv) into an expression vector and introduce the DNA sequence encoding the human IgG1 Fc region into the same expression vector, downstream of the mouse scFv sequence, creating a fusion construct that consists of the scFv followed by the Fc region. The recombinant vector was transfected into a host cell line for expression. The S recombinant monoclonal antibodies were purified from the cell culture supernatant using affinity chromatography. The binding specificity and affinity of the S recombinant monoclonal antibody were confirmed using various applications including ELISA, GICA, and neutralizing. This antibody specifically recognizes the human SARS-CoV-2 S protein.

Customer Reviews and Q&A

 Customer Reviews
Average Rating:
5.0 - 1 reviews

Submit a Review here

Applications : Fabrication of MO CM Biochips

Sample type: magneto-optical biochip

Review: the antibody of spike glycoprotein (anti-S, 10 μg/mL, 40 μL) was added and conjugated with GA. Te absorption peaks of the biochip after the fabrication process of Au nanostructure,  APTMS, GA and BSA are 532 nm, 537 nm, 538 nm and 547 nm, respectively.

By Anonymous

Target Background

Function
attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein. Binding to host NRP1 and NRP2 via C-terminal polybasic sequence enhances virion entry into host cell. This interaction may explain virus tropism of human olfactory epithelium cells, which express high level of NRP1 and NRP2 but low level of ACE2. The stalk domain of S contains three hinges, giving the head unexpected orientational freedom. Uses human TMPRSS2 for priming in human lung cells which is an essential step for viral entry. Can be alternatively processed by host furin. Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes.; mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes.; Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis.; May down-regulate host tetherin (BST2) by lysosomal degradation, thereby counteracting its antiviral activity.
Gene References into Functions
  1. Study presents crystal structure of C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike S protein in complex with human ACE2 (hACE2); hACE2-binding mode similar overall to that observed for SARS-CoV. However, details at the binding interface show that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-CoV receptor-binding domain. PMID: 32378705
  2. crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cell receptor ACE2 PMID: 32365751
  3. crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 (engineered to facilitate crystallization) in complex with ACE2 PMID: 32320687
  4. Out of the two isolates from India compared to the isolates from Wuhan, China, one was found to harbor a mutation in its receptor-binding domain (RBD) at position 407 where, arginine was replaced by isoleucine. This mutation has been seen to change the secondary structure of the protein at that region and this can potentially alter receptor binding of the virus. PMID: 32275855
  5. Structural modeling of the SARS-CoV-2 spike glycoprotein show similar receptor utilization between SARS-CoV-2 and SARS-CoV, despite a relatively low amino acid similarity in the receptor binding module. Compared to SARS-CoV and all other coronaviruses in Betacoronavirus lineage B, an extended structural loop containing basic amino acids were identified at the interface of the receptor binding (S1) and fusion (S2) domains. PMID: 32245784
  6. crystal structure of CR3022, a neutralizing antibody from a SARS patient, in complex with the receptor-binding domain of the SARS-CoV-2 spike (S) protein to 3.1 A; study provides insight into how SARS-CoV-2 can be targeted by the humoral immune response and revealed a conserved, but cryptic epitope shared between SARS-CoV-2 and SARS-CoV PMID: 32225176
  7. SARS-CoV and SARS-CoV-2 spike proteins have comparable binding affinities achieved by balancing energetics and dynamics. The SARS-CoV-2-ACE2 complex contains a higher number of contacts, a larger interface area, and decreased interface residue fluctuations relative to the SARS-CoV-ACE2 complex. PMID: 32225175
  8. Interaction interface between cat/dog/pangolin/Chinese hamster ACE2 and SARS-CoV/SARS-CoV-2 S protein was simulated through homology modeling. Authors identified that N82 of ACE2 showed closer contact with receptor-binding domain of S protein than human ACE2. PMID: 32221306
  9. SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs; determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer. PMID: 32201080
  10. Study demonstrates that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. PMID: 32155444
  11. The ACE2-B0AT1 complex exists as a dimer of heterodimers. Structural alignment of the RBD-ACE2-B0AT1 ternary complex with the S protein of SARS-CoV-2 suggests that two S protein trimers can simultaneously bind to an ACE2 homodimer. PMID: 32142651
  12. study demonstrated SARS-CoV-2 S protein entry on 293/hACE2 cells is mainly mediated through endocytosis, and PIKfyve, TPC2 and cathepsin L are critical for virus entry; found that SARS-CoV-2 S protein could trigger syncytia in 293/hACE2 cells independent of exogenous protease; there was limited cross-neutralization activity between convalescent sera from SARS and COVID-19 patients PMID: 32132184
  13. study determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation; provided biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S PMID: 32075877

Show More

Hide All

Subcellular Location
Virion membrane; Single-pass type I membrane protein. Host endoplasmic reticulum-Golgi intermediate compartment membrane; Single-pass type I membrane protein. Host cell membrane; Single-pass type I membrane protein.
Protein Families
Betacoronaviruses spike protein family
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*